Drug Profile
Cretostimogene grenadenorepvec - CG Oncology
Alternative Names: CG-0070Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Cell Genesys; Genetic Therapy
- Developer CG Oncolgy; Lepu Biopharma
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bladder cancer
- No development reported Solid tumours
Most Recent Events
- 12 Feb 2024 H. Lee Moffitt Cancer Center and Research Institute initiates a phase Ib trial for Bladder cancer in USA (Intravesicular) (NCT06253845)
- 05 Dec 2023 Cretostimogene grenadenorepvec - CG Oncology receives Breakthrough Therapy status for Bladder cancer (Monotherapy, Second-line therapy or greater) in USA
- 05 Dec 2023 Cretostimogene grenadenorepvec - CG Oncology receives Fast Track designation for Bladder cancer [Intravesicular] (Monotherapy, Second-line therapy or greater) in USA